Date: Thursday, September 19 at 11 a.m. ET (1 hour)
- Keith Meadows, PhD, DHP Research
- Paul O’Donohoe, Director Health Outcomes, CRF Health
Diabetes has rapidly become a global epidemic affecting more than 238 million people and is expected to increase to 438 million people by the year 2030.
As such, biopharmaceutical companies and researchers around the world are working to identify new, effective and safe treatments to help this growing patient population. As a consequence patient reported outcomes (PRO) measures are increasingly being used to measure health status, quality of life, and the economic burden of the disease.
One such instrument is the DHP-18, which as a measure of the psychological and behavioural impact of living with diabetes was initially developed as a patient self-completion instrument for use across a range of settings including clinical trials, population and community survey and research studies. The DHP was recently adopted by the Department of Health into the next generation PROMs program for the NHS.
What you will learn:
- The psychological impact on adherence and control
- PROs in real world data collection
- Disease-specific versus generic — making the choice
- The Diabetes Health Profile (DHP) and what it measures